Britain’s largest drugstore chain Boots has set a Feb. 24 deadline to receive indicative bids from a series of deep-pocketed investors that could value the 173-year-old firm at up to 8 billion pounds ($10.88 billion), two sources told Reuters.
The sale will see US drugstore giant Walgreens, which has backed Nottingham-based Boots since 2012, cashing out from one of Britain’s best-known retailers which operates more than 2,200 stores and employs about 51,000 people.
It will also lead to the dismantling of the Walgreens Boots Alliance (WBA), which was set up in 2014 when Walgreens took full control of the health and beauty chain, creating a global behemoth with overall revenues of $132.5 billion in 2021.
A spokesperson said on Jan. 11 that the company was undertaking a strategic review primarily focused on Boots, but also including skincare and cosmetics brand No7 which was launched by Boots in 1935.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan